- Home
- FFWM vs KROS Comparison
FFWM vs KROS Comparison
Compare FFWM & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFWM
- KROS
- Stock Information
- Founded
- FFWM 1990
- KROS 2015
- Country
- FFWM United States
- KROS United States
- Employees
- FFWM N/A
- KROS N/A
- Industry
- FFWM Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- FFWM Finance
- KROS Health Care
- Exchange
- FFWM Nasdaq
- KROS Nasdaq
- Market Cap
- FFWM 409.3M
- KROS 460.6M
- IPO Year
- FFWM 2014
- KROS 2020
- Fundamental
- Price
- FFWM $5.08
- KROS $11.00
- Analyst Decision
- FFWM Buy
- KROS Buy
- Analyst Count
- FFWM 4
- KROS 11
- Target Price
- FFWM $6.75
- KROS $45.33
- AVG Volume (30 Days)
- FFWM 516.6K
- KROS 2.1M
- Earning Date
- FFWM 01-30-2025
- KROS 02-26-2025
- Dividend Yield
- FFWM 0.20%
- KROS N/A
- EPS Growth
- FFWM N/A
- KROS N/A
- EPS
- FFWM N/A
- KROS N/A
- Revenue
- FFWM $96,072,000.00
- KROS $651,000.00
- Revenue This Year
- FFWM N/A
- KROS $303.27
- Revenue Next Year
- FFWM $12.65
- KROS N/A
- P/E Ratio
- FFWM N/A
- KROS N/A
- Revenue Growth
- FFWM N/A
- KROS 8037.50
- 52 Week Low
- FFWM $4.66
- KROS $9.78
- 52 Week High
- FFWM $8.72
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- FFWM 29.74
- KROS 24.79
- Support Level
- FFWM $4.66
- KROS $11.04
- Resistance Level
- FFWM $6.46
- KROS $11.99
- Average True Range (ATR)
- FFWM 0.30
- KROS 0.60
- MACD
- FFWM -0.09
- KROS 1.20
- Stochastic Oscillator
- FFWM 22.93
- KROS 43.99
About FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.